Testing Allows Researchers to Determine Possibility of Drug-Drug Interactions Before Clinical Trials State College, PA (19 June 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the addition of the Human MDR-1 / P-Glycoprotein Drug Interaction Assay to their portfolio. This kit expands INDIGO’s
By combining the advantages of upcyte hepatocytes with INDIGO’s industry-leading platform and science, the new hepatotoxicty assay kit helps researchers get the information they need to confidently advance their discovery processes.
Portfolio Expansion Helps Researchers Move to the Next Stage of Discovery Faster State College, PA (December 5, 2018) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor research, announced the addition of a gene expression assay kit featuring upcyte® hepatocytes to their portfolio. This addition both complements INDIGO’s industry-leading nuclear receptor assays and
Most Valued Company Award Presented During Angel Capital Expo State College, PA (October 30, 2017) – INDIGO Biosciences, Inc. is pleased to announce that it was awarded the Stephen M. Goodman Most Valued Company Award at the Keiretsu Forum Angel Capital Expo. The Expo took place October 19, 2017 at the Union League in Philadelphia,